Antibody Fc mutants with ablated effector functions
AssigneeJanssen Biotech, Inc.
InventorsMcCarthy Stephen, Bernard Scallon, William Strohl, Susan Tam, Omid Vafa
Life of this patent
Estimating the term…
Abstract
Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to Fc gamma receptors and resulting activity and can be used in the treatment of various diseases and disorders.
Claims5
An isolated polynucleotide encoding an Fc-containing molecule, comprising a mutated IgG1 Fc domain and having binding reduced by at least 800 fold or undetectable binding to a Fcγ receptor (FcγR), selected from the group consisting of FcγRI, FcγRIIa-H131 variant, FcγRIIa-R131 variant, FcγRIIb, and FcγRIII-V158 variant, as compared to an Fc-containing molecule with a wild type IgG1 Fc domain, wherein the mutated IgG1 Fc comprises the mutations L234A, L235A, G237A P238S, H268A, A330S, and P331S, wherein the binding is measured by conjugating the Fc-containing molecule and the FcγR to a donor and an acceptor beads and by measuring the energy transfer between the donor and the acceptor beads using ALPHASCREEN® assay.
Dependencies are inferred from the claim text.